Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
p-muc1c-allo1
- Development stage
- Phase 1
- Lead developer
- Roche
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
P-MUC1C-ALLO1 is a fully allogeneic chimeric antigen receptor T cell (CAR-T) therapy designed to target the Mucin 1 C-terminal subunit (MUC1-C) epitope, which is overexpressed and aberrantly glycosylated in many epithelial-derived solid tumors. The product uses a nonviral piggyBac transposon-based DNA delivery system to generate CAR-T cells highly enriched for the T stem cell memory phenotype, aiming for improved persistence and antitumor activity. It is being developed by Poseida Therapeutics for the treatment of multiple solid tumors, including breast, colorectal, lung, ovarian, pancreatic, renal cancers and other malignancies expressing cancer-specific MUC1-C. The therapy is currently in Phase 1 clinical trials evaluating safety and preliminary efficacy in adults with advanced or metastatic epithelial-derived solid tumors refractory to standard therapies[3][4][5][6][7].
- Other names
- p-muc1c-allo1p-muc-1c-allo1p-muc 1c-allo1
02
Targets
MUC1-C (Mucin-1 C-terminal subunit)
Beyond the preview
Go deeper on p-muc1c-allo1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on p-muc1c-allo1.